Citi Pharma (KAR:CPHL) 5-Year Yield-on-Cost %: 4.80 (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨72.36
! 1 Warning Sign
View Full Analysis

What is Citi Pharma 5-Year Yield-on-Cost %?

Citi Pharma KAR:CPHL -0.69% 15 5-Year Yield-on-Cost % is 4.80 as of Aug. 18, 2026. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 509 Drug Manufacturers companies, Citi Pharma ranks better than 70.92% on this metric.

Citi Pharma's yield on cost for the quarter that ended in . 20 was 4.80.


The historical rank and industry rank for Citi Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:

KAR:CPHL' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 4.99
Current: 4.8


During the past 0 years, Citi Pharma's highest Yield on Cost was 4.99. The lowest was 0.00. And the median was 0.00.


KAR:CPHL's 5-Year Yield-on-Cost % is ranked better than
70.92% of 509 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs KAR:CPHL: 4.80

Citi Pharma  (KAR:CPHL) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Citi Pharma 5-Year Yield-on-Cost % Related Terms


KAR:CPHL vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citi Pharma 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Citi Pharma's 5-Year Yield-on-Cost % falls into.


KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Citi Pharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 4.80 mean?
Citi Pharma (KAR:CPHL) has a 5-Year Yield-on-Cost % of 4.80 as of Aug. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Citi Pharma and its competitors. According to the industry distribution chart, Citi Pharma ranks #148 out of 509 companies in the Drug Manufacturers industry, placing it in the top 29.1%.
Is Citi Pharma's 5-Year Yield-on-Cost % too high?
Citi Pharma's current 5-Year Yield-on-Cost % is 4.80. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Citi Pharma's value of 4.80 is 109.6% above this industry median. Based on the distribution chart, Citi Pharma ranks #148 out of 509 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Citi Pharma ranks #148 out of 509 companies for 5-Year Yield-on-Cost %. This puts Citi Pharma in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Citi Pharma's value of 4.80 is 109.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citi Pharma's current 5-Year Yield-on-Cost % of 4.80 is 109.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Citi Pharma and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citi Pharma's current 5-Year Yield-on-Cost % is 4.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current 5-Year Yield-on-Cost % of 4.80. The current 5-Year Yield-on-Cost % is 4.80 and 109.6% above the Drug Manufacturers industry median of 2.29. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current 5-Year Yield-on-Cost % is 4.80 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨72.36
Price